Wen Cheng

Wen Cheng

Auto-generated profile, based on publicly available information

Wen Cheng

Department of Traditional Chinese Gynecology

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 March 2021 in Evidence-Based Complementary and Alternative Medicine
Verified
Journal Article
Open access
PDF file
ZNZhexin Ni
Zhexin Ni
WCWen Cheng
Wen Cheng
JDJie Ding
Jie Ding
RYRuipin Yao
Ruipin Yao
DZDanying Zhang
Danying Zhang
CYChaoqin Yu
Chaoqin Yu
Gut microbiota disorders are closely related to polycystic ovarian syndrome (PCOS). Buzhong Yiqi prescription (BZYQ) has a significant clinical effect on the treatment of patients with obesity exhibiting PCOS and phlegm-dampness syndrome caused by spleen deficiency (SPSD). Hence, this study aimed to explore gut microbiota and fecal metabolite alterations in such patients treated with BZYQ. Fifty eligible patients with obesity manifesting PCOS and SPSD participated and agreed to undergo 3 months of BZYQ treatment. Results showed that BZYQ significantly alleviated the serum dehydroepiandrosterone sulfate and testosterone levels and markedly changed the gut microbiota structure in these patients. Furthermore, 106 differential fecal metabolites and 14 KEGG enrichment pathways were quantified. The phylum Spirochaetae and the genera [Eubacterium]_rectale_group, Escherichia-Shigella, and Fusicatenibacter were significantly more abundant, but Megamonas was significantly less abundant after treatment than before treatment. Disorders in the gut microbiota and fecal metabolites of these patients were closely related to hyperandrogenemia and insulin resistance. In conclusion, BZYQ could ameliorate the serum androgen level and had an impact on the gut microbiota and metabolites in patients with obesity manifesting PCOS and SPSD.

1 January 2021 in BioMed Research International
Verified
Journal Article
Open access
PDF file
LCLu Chen
Lu Chen
ZNZhexin Ni
Zhexin Ni
ZCZailong Cai
Zailong Cai
WCWen Cheng
Wen Cheng
SSShuai Sun
Shuai Sun
JYJin Yu
Jin Yu
Objective. To explore the mechanisms of follicular fluids (FFs) on granulose cell (GC) apoptosis in endometriosis‐associated infertility. Materials and Methods. 60 infertile women were enrolled. The FFs from 30 endometriosis‐associated infertility (EI) patients were collected and processed by ELISA hormone assay and proteomic profiling. The ovary GCs collected from 30 tubal‐associated infertility (TI) patients were cultured in follicular fluids of endometriosis‐associated infertility patients (EI‐FFs), and the apoptosis mechanisms were explored by flow cytometry assay, real‐time PCR, Western blotting, and protein–protein interaction (PPI) network analysis. Results. Our results showed that the expression of 22 specific proteins was significantly different in the FFs from EI and TI patients, and the level of testosterone and anti‐Müllerian hormone was not obviously different between the two groups. EI‐FFs could accelerate the apoptosis process of granulose cells of tubal‐associated infertility patients (TI‐GCs) by regulating the expression of 5 apoptosis‐related proteins including BCL2, BAX, CASP3, CASP9, and TP53. The correlation of these 22 specific proteins and 5 apoptosis‐related proteins was analyzed by PPI, and 5 protein biomarkers (INS, CXCL10, ICAM1, WIF1, and TNFRSF13C) and 5 signaling pathways (cytokine‐cytokine receptor interaction, apoptosis, regulation of actin cytoskeleton, MAPK, and p53 signaling pathway) were predicted. Conclusion. This research clarified the effect and explored the mechanisms of EI‐FFs on the apoptosis of TI‐GCs and indicated the protein biomarkers and signaling pathways for further study.

1 June 2018 in OncoTargets and Therapy
Verified
Journal Article
Open access
PDF file
ALAnji Li
Anji Li
SSShuai Sun
Shuai Sun
TSTao Song
Tao Song
XLXi Li
Xi Li
WCWen Cheng
Wen Cheng
CYChaoqin Yu
Chaoqin Yu
Background: Ovarian adenosquamous carcinoma is an extremely rare type of ovarian histology. Platinum-refractory disease is also uncommon, but can be fatal because of the lack of available treatment options. To date, there is no study or case report on platinum-refractory ovarian adenosquamous carcinoma or its relevant treatment. Case presentation: Herein, we report the case of a 38-year-old Chinese woman with platinum-refractory advanced ovarian adenosquamous carcinoma who received clinical benefit from poly adenosine diphosphate ([ADP] ribose) polymerase and programmed death-1 inhibitors after failure of prior multiline chemotherapies and antiangiogenic agents. The targeted therapy and immunotherapy-controlled disease deterioration and improved performance status. Thus far, the patient has survived longer than 15 months, and she is taking nivolumab as maintenance treatment. Conclusion: Targeted therapy and immunotherapy may be options for rare categories of ovarian cancer, but this warrants more clinical evidence of efficacy and toxicity.